337 related articles for article (PubMed ID: 35154513)
1. Prognosis Risk Model Based on Pyroptosis-Related lncRNAs for Bladder Cancer.
Lu Z; Tang F; Li Z; Lai Y; Lu Z; Zhang J; Tang Z; Cai W; He Z
Dis Markers; 2022; 2022():7931393. PubMed ID: 35154513
[TBL] [Abstract][Full Text] [Related]
2. Identifying a Novel Defined Pyroptosis-Associated Long Noncoding RNA Signature Contributes to Predicting Prognosis and Tumor Microenvironment of Bladder Cancer.
Lu H; Wu J; Liang L; Wang X; Cai H
Front Immunol; 2022; 13():803355. PubMed ID: 35154117
[TBL] [Abstract][Full Text] [Related]
3. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
[TBL] [Abstract][Full Text] [Related]
4. m6A-immune-related lncRNA prognostic signature for predicting immune landscape and prognosis of bladder cancer.
Feng ZH; Liang YP; Cen JJ; Yao HH; Lin HS; Li JY; Liang H; Wang Z; Deng Q; Cao JZ; Huang Y; Wei JH; Luo JH; Chen W; Chen ZH
J Transl Med; 2022 Oct; 20(1):492. PubMed ID: 36309694
[TBL] [Abstract][Full Text] [Related]
5. A pyroptosis-related lncRNA signature in bladder cancer.
Wang P; Wang Z; Zhu L; Sun Y; Castellano L; Stebbing J; Yu Z; Peng L
Cancer Med; 2023 Mar; 12(5):6348-6364. PubMed ID: 36237132
[TBL] [Abstract][Full Text] [Related]
6. Integrated analysis on the N6-methyladenosine-related long noncoding RNAs prognostic signature, immune checkpoints, and immune cell infiltration in clear cell renal cell carcinoma.
Qiu Y; Wang X; Fan Z; Zhan S; Jiang X; Huang J
Immun Inflamm Dis; 2021 Dec; 9(4):1596-1612. PubMed ID: 34432955
[TBL] [Abstract][Full Text] [Related]
7. A robust signature of immune-related long non-coding RNA to predict the prognosis of bladder cancer.
Lai C; Wu Z; Li Z; Yu H; Li K; Tang Z; Liu C; Xu K
Cancer Med; 2021 Sep; 10(18):6534-6545. PubMed ID: 34374227
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of pyroptosis-related lncRNAs prediction model for bladder cancer.
Lia T; Shao Y; Regmi P; Li X
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 35024796
[TBL] [Abstract][Full Text] [Related]
9. Identification of a pyroptosis-associated long non-coding RNA signature for predicting the immune status and prognosis in skin cutaneous melanoma.
Wu L; Liu G; He YW; Chen R; Wu ZY
Eur Rev Med Pharmacol Sci; 2021 Sep; 25(18):5597-5609. PubMed ID: 34604952
[TBL] [Abstract][Full Text] [Related]
10. A pyroptosis-related lncRNA signature predicts prognosis and immune microenvironment in head and neck squamous cell carcinoma.
Zhu W; Ye Z; Chen L; Liang H; Cai Q
Int Immunopharmacol; 2021 Dec; 101(Pt B):108268. PubMed ID: 34688154
[TBL] [Abstract][Full Text] [Related]
11. Development of a Novel Pyroptosis-Associated lncRNA Biomarker Signature in Lung Adenocarcinoma.
Wang P; Wang Z; Lin Y; Castellano L; Stebbing J; Zhu L; Peng L
Mol Biotechnol; 2024 Feb; 66(2):332-353. PubMed ID: 37154865
[TBL] [Abstract][Full Text] [Related]
12. Construction of prognostic risk model of bladder cancer based on cuproptosis-related long non-coding RNAs.
Xu C; Chen A; Mao C; Cui B
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 52(2):139-147. PubMed ID: 37283097
[TBL] [Abstract][Full Text] [Related]
13. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
Peng Y; Wang H; Huang Q; Wu J; Zhang M
J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
[TBL] [Abstract][Full Text] [Related]
14. A novel molecular subtypes and risk model based on inflammatory response-related lncrnas for bladder cancer.
Tang F; Zhang J; Lu Z; Liao H; Hu C; Mai Y; Lai Y; Lu Z; Tang Z; Li Z; He Z
Hereditas; 2022 Aug; 159(1):32. PubMed ID: 35964079
[TBL] [Abstract][Full Text] [Related]
15. Identification of a pyroptosis-related lncRNA risk model for predicting prognosis and immune response in colon adenocarcinoma.
Tan Y; Lu L; Liang X; Chen Y
World J Surg Oncol; 2022 Apr; 20(1):118. PubMed ID: 35413978
[TBL] [Abstract][Full Text] [Related]
16. N6-methyladenosine-related lncRNAs identified as potential biomarkers for predicting the overall survival of Asian gastric cancer patients.
Xu S; Chen W; Wang Y; Zhang Y; Xia R; Shen J; Gong X; Liang Y; Xu J; Tang H; Zhao T; Zhang Y; Chen T; Wang C
BMC Cancer; 2022 Jul; 22(1):721. PubMed ID: 35778697
[TBL] [Abstract][Full Text] [Related]
17. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
Li L; Xie R; Lu G
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
[TBL] [Abstract][Full Text] [Related]
18. Construction and Validation of Pyroptosis-Related lncRNA Prediction Model for Colon Adenocarcinoma and Immune Infiltration Analysis.
Liu Q; Chen N; Liu L; Zheng Q; Liao W; Zhao M; Zeng J; Tang J
Dis Markers; 2022; 2022():4492608. PubMed ID: 36168326
[TBL] [Abstract][Full Text] [Related]
19. Identification and verification of an immune-related lncRNA signature for predicting the prognosis of patients with bladder cancer.
Wang J; Shen C; Dong D; Zhong X; Wang Y; Yang X
Int Immunopharmacol; 2021 Jan; 90():107146. PubMed ID: 33189610
[TBL] [Abstract][Full Text] [Related]
20. Identification of pyroptosis-related lncRNA subtype and signature predicts the prognosis in bladder cancer.
Zeng T; Ye J; Wang H; Tian W
Medicine (Baltimore); 2023 Oct; 102(42):e35195. PubMed ID: 37861525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
